INTERNAL CREDIT MEMORANDUM

Borrower:

Johnson & Johnson (JNJ)

Date:

2026-02-19

Sector:

Healthcare

Analyst:

Credit Risk AI

Rating:

Outlook:

Stable

Executive Summary

Johnson & Johnson maintains a robust credit profile with strong liquidity and manageable leverage ratios. Recent financial performance indicates stable cash flow generation capable of supporting current debt obligations.

Financial Analysis (3-Year Trend)

Metric	2023	2024	2025
Revenue ($B)	388.2	419.51	453.33
EBITDA ($B)	38.53	34.27	44.51
Total Debt ($B)	57.25	40.74	81.1
Leverage (Debt/EBITDA)	1.49x	1.19x	1.82x
Interest Coverage	13.5x	16.8x	11.0x

Risk Assessment

Primary Risks:

Cyclical downturn in Healthcare.
Regulatory changes affecting margins.
Execution risk on new product launches.

Mitigants:

Strong liquidity position with $68.0B in cash.
Demonstrated access to capital markets.
Leading market share in core segments.

Recommendation

Based on the quantitative credit scoring model (Score: 94/100) and qualitative review of JNJ's 10-K filings, we recommend MAINTAIN exposure at current levels.

SYSTEM AUDIT LOG
Transaction ID: 92b5c060-40c7-40ac-b74f-1a0fddab6306
Model: Credit-BERT-v2 (Fine-tuned on S&P Ratings)
Data Integrity: Verified (Hash: 976fa0ccaeab6f29)
RAG Sources: 11 Documents Processed